Neurogene Inc.

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
34.01 ^USD	+2.10%		+11.00%	+75.49%

May. 10	Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 07	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	CI

Neoleukin Therapeutics, Inc. Announces Resignation of Robert Ho as Chief Financial Officer, Effective March 1, 2022

February 15, 2022 at 08:31 am EST

Neoleukin Therapeutics, Inc. announced resignation of Robert Ho as Chief Financial Officer to pursue another opportunity, effective March 1, 2022.

Latest news about Neurogene Inc.

Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	May. 07	CI
Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target	Apr. 29	MT
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
William Blair Initiates Neurogene With Outperform Rating	Mar. 21	MT
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	Mar. 04	CI
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	Feb. 21	CI
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer	Jan. 17	CI
Neurogene Names Julie Jordan as Chief Medical Officer	Jan. 16	MT
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	Jan. 16	CI
HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target	Jan. 08	MT
Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target	Jan. 05	MT
Neurogene Announces Business Update and 2024 Outlook	Jan. 05	CI
Neurogene Completes Merger With Neoleukin Therapeutics	Dec. 19	MT
Neoleukin Therapeutics, Inc.(NasdaqCM:NLTX) dropped from NASDAQ Composite Index	Dec. 18	CI
Neurogene Inc. announced that it has received $95 million in funding from a group of investors	Dec. 17	CI
Neurogene Inc. completed the acquisition of Neoleukin Therapeutics, Inc. from a group of shareholders for approximately $120 million in a reverse merger transaction.	Dec. 17	CI
Neoleukin Therapeutics Board Approves Reverse Stock Split, Increase in Authorized Common Stock Capital to 500 Million	Dec. 15	MT
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Sector Update: Health Care Stocks Rise Slightly Late Afternoon	23-09-22	MT
Sector Update: Health Care Stocks Mixed Friday Afternoon	23-09-22	MT
Neoleukin Therapeutics Board Approves 1-for-5 Reverse Stock Split	23-09-22	MT
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI

Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Sector

Biotechnology & Medical Research

Calendar

2024-06-12 - Goldman Sachs Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.01 USD

Average target price

51.25 USD

Spread / Average Target

+50.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEUROGENE INC.	+75.49%	429M
MODERNA, INC.	+41.79%	50.93B
IQVIA HOLDINGS INC.	-0.56%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-7.20%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	18.9B
BIO-TECHNE CORPORATION	+6.92%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.17B
MEDPACE HOLDINGS, INC.	+29.60%	12.16B

Other Biotechnology & Medical Research

Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Neoleukin Therapeutics, Inc. Announces Resignation of Robert Ho as Chief Financial Officer, Effective March 1, 2022

Latest news about Neurogene Inc.

Chart Neurogene Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research